POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
A Pozniak, K Arastéh, JM Molina, B Grinsztejn, S De Meyer, T De Van Casteele, S Spinosa-GuzmanVolume:
11
Langue:
english
Pages:
1
DOI:
10.1186/1758-2652-11-s1-p24
Date:
November, 2008
Fichier:
PDF, 71 KB
english, 2008
File converter
Plus de résultats de recherche
More benefits 
